Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.

Castelo-Branco P, Passer BJ, Buhrman JS, Antoszczyk S, Marinelli M, Zaupa C, Rabkin SD, Martuza RL.

Gene Ther. 2010 Jun;17(6):805-10. doi: 10.1038/gt.2010.20. Epub 2010 Mar 11.

2.

Oncolytic virus therapy using genetically engineered herpes simplex viruses.

Todo T.

Front Biosci. 2008 Jan 1;13:2060-4. Review.

PMID:
17981691
3.

Advance in herpes simplex viruses for cancer therapy.

Liu S, Dai M, You L, Zhao Y.

Sci China Life Sci. 2013 Apr;56(4):298-305. doi: 10.1007/s11427-013-4466-4. Epub 2013 Apr 7. Review.

PMID:
23564184
4.

Oncolytic herpes simplex virus therapy for peripheral nerve tumors.

Jeyaretna DS, Rabkin SD, Martuza RL.

Neurosurg Focus. 2007 Jun 15;22(6):E4. Review.

PMID:
17613221
5.

Fusogenic oncolytic herpes simplex viruses as a potent and personalized cancer vaccine.

Li QX, Liu G, Zhang X.

Curr Pharm Biotechnol. 2012 Jul;13(9):1773-85. Review.

PMID:
21740353
6.
7.

Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy.

Ning J, Wakimoto H.

Front Microbiol. 2014 Jun 20;5:303. doi: 10.3389/fmicb.2014.00303. eCollection 2014. Review.

8.

Design and application of oncolytic HSV vectors for glioblastoma therapy.

Grandi P, Peruzzi P, Reinhart B, Cohen JB, Chiocca EA, Glorioso JC.

Expert Rev Neurother. 2009 Apr;9(4):505-17. doi: 10.1586/ern.09.9. Review.

9.

Employing tumor hypoxia for oncolytic therapy in breast cancer.

Chun YS, Adusumilli PS, Fong Y.

J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):311-8. Review.

PMID:
16826462
10.

Oncolytic virus therapy for prostate cancer.

Fukuhara H, Homma Y, Todo T.

Int J Urol. 2010 Jan;17(1):20-30. doi: 10.1111/j.1442-2042.2009.02383.x. Epub 2009 Oct 13. Review.

11.

Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy.

Yin J, Markert JM, Leavenworth JW.

Front Oncol. 2017 Jun 26;7:136. doi: 10.3389/fonc.2017.00136. eCollection 2017. Review.

12.

Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?

Kanai R, Wakimoto H, Cheema T, Rabkin SD.

Future Oncol. 2010 Apr;6(4):619-34. doi: 10.2217/fon.10.18. Review.

13.

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs.

Braidwood L, Graham SV, Graham A, Conner J.

Oncolytic Virother. 2013 Dec 4;2:57-74. doi: 10.2147/OV.S52601. eCollection 2013. Review.

14.

Herpes simplex virus oncolytic therapy for pediatric malignancies.

Friedman GK, Pressey JG, Reddy AT, Markert JM, Gillespie GY.

Mol Ther. 2009 Jul;17(7):1125-35. doi: 10.1038/mt.2009.73. Epub 2009 Apr 14. Review.

15.

Preclinical Mouse Models for Analysis of the Therapeutic Potential of Engineered Oncolytic Herpes Viruses.

Speranza MC, Kasai K, Lawler SE.

ILAR J. 2016;57(1):63-72. doi: 10.1093/ilar/ilw002. Review.

16.

Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors.

Nishio N, Dotti G.

Oncoimmunology. 2015 Mar 6;4(2):e988098. eCollection 2015 Feb. Review.

Supplemental Content

Support Center